Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinew PharmaROCO:6634 +0.17%25 FCF Yield % is -2.33 as of Aug. 23, 2026. GuruFocus rates ROCO:6634 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Sinew Pharma ranks better than 73.48% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sinew Pharma FCF Yield % Related Terms
Sinew Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Sinew Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6634 vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Sinew Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinew Pharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinew Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sinew Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinew Pharma (ROCO:6634) has a FCF Yield % of -2.33 as of Aug. 23, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sinew Pharma and its competitors. According to the industry distribution chart, Sinew Pharma ranks #374 out of 1410 companies in the Biotechnology industry, placing it in the top 26.5%.
Is Sinew Pharma's FCF Yield % too high?
Sinew Pharma's current FCF Yield % is -2.33. Based on the distribution chart, Sinew Pharma ranks #374 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinew Pharma ranks #374 out of 1410 companies for FCF Yield %. This puts Sinew Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sinew Pharma and its competitors. Sinew Pharma's current FCF Yield % is -2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current FCF Yield % of -2.33. The current FCF Yield % is -2.33. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current FCF Yield % is -2.33 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score
Get the complete analysis for ROCO:6634
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6634 has been successfully added to your 
